Gut Check: How Your Genes & H. pylori Could Increase Gastric Cancer Risk
"New research highlights the interplay between a common stomach bacteria and your genetic makeup in determining susceptibility to gastric cancer, particularly in Southern China."
Gastric cancer remains a significant global health threat, ranking among the leading causes of cancer-related deaths worldwide. While factors like diet and lifestyle play a role, Helicobacter pylori (H. pylori), a common bacterium that infects the stomach, is a well-established major culprit.
However, the story isn't quite that simple. Only a fraction of individuals infected with H. pylori go on to develop gastric cancer, suggesting that other factors are at play. One area of increasing interest is the role of genetics, specifically how variations in our genes might influence our susceptibility to the disease.
Now, a recent study published in the International Journal of Clinical Oncology sheds light on the complex interaction between H. pylori infection and a specific genetic polymorphism in the toll-like receptor 2 (TLR2) gene, potentially increasing gastric cancer risk in the Southern Chinese population. This article breaks down the key findings of this research and what it might mean for you.
H. pylori and the Global Cancer Burden
Helicobacter pylori infects around half of the world’s population and is identified as the most severe known risk factor for gastric cancer. Gastric cancer is the second-highest cause of cancer-related deaths globally. A 2023 systematic review and meta-analysis set out to assess gastric cancer prevalence among people infected with H. pylori. A separate 2025 study aimed to estimate the share of 2022 cases and deaths attributable to H. pylori across countries.
Testing and Risk Assessment
Reliable detection of H. pylori is important because the infection is linked to peptic ulcer disease, gastric MALT lymphoma, and gastric cancer. A 2026 article argues that validating a “gold standard” with a single test has limitations and advocates considering multimodal testing for initial screening in high-risk groups and for confirmation. The ABC method may help identify high-risk cases and assess infection status and future gastric cancer risk, particularly for people who decline endoscopy or have undergone it, but the source emphasizes that its limitations should be recognized. Risk is highest when infection occurs alongside factors such as gastric atrophy or intestinal metaplasia, a first-degree family history, or origin from a high-incidence region.
Decoding the Genetic Link: TLR2 and Gastric Cancer
The study, conducted in Southern China, focused on a genetic variation known as the TLR2-196 to -174 ins/del polymorphism. TLR2 is a key component of our immune system, acting as a receptor that recognizes and responds to invading pathogens like H. pylori. This genetic variation involves the presence or absence (insertion or deletion) of a small piece of DNA in the TLR2 gene.
- Increased Risk: Individuals with the del/del genotype had a 2.59 times higher risk of developing gastric cancer compared to those with the ins/ins genotype.
- Intestinal Subtype: The del/del genotype was particularly associated with an increased risk of intestinal gastric cancer, a common subtype linked to H. pylori infection.
- Synergistic Effect: The combination of the del/del genotype and H. pylori infection resulted in a synergistic effect, further elevating the risk of gastric cancer. Those with both factors had a 3.04 times higher risk compared to those without either.
- No Impact on Survival: Interestingly, the study found no association between the TLR2 polymorphism and overall survival in gastric cancer patients.
Mechanisms Under Investigation
Research on how H. pylori contributes to gastric cancer continues to expand, with a 2025 review summarizing molecular and pathogenetic mechanisms and identifying gaps that warrant further investigation. Another 2025 review examines the role of pathogenic microbes, including H. pylori and other bacteria, in gastric carcinogenesis. In the acute phase of H. pylori infection, the cited TLR review reports increased TLR2 expression on gastric epithelial cells; activation of NF-κB signaling is associated with IL-8 secretion and production of inflammatory mediators.
H. pylori and Other Gastrointestinal Cancers
A 2024 review describes H. pylori as a gastric bacterium extensively studied for its associations with gastritis, peptic ulcers, and gastric cancer. The review notes that recent evidence suggests the bacterium may also have potent associations beyond those established conditions. The provided source excerpt does not specify which additional cancers or comparative risk estimates it discusses.
What Does This Mean for You?
While this study provides valuable insights into the genetic factors influencing gastric cancer risk, it's important to remember that it was conducted in a specific population (Southern China). More research is needed to confirm these findings in other ethnic groups and to fully understand the underlying mechanisms.
A Growing Research Base
A 2023 systematic review and meta-analysis aimed to update evidence on the association between H. pylori infection and gastric cancer. It searched PubMed, Embase, and the Cochrane Library for studies published from 1990 through December 2021. Separately, Nature Index’s topic page describes a graph tracking yearly article counts on H. pylori infections and gastrointestinal cancer risk across all publications, not only Nature Index journals; the supplied material does not provide the counts or trend.
Eradication and Prevention
A 2026 Gastric Cancer Foundation article reports that treating H. pylori can reduce the risk of developing gastric cancer, while noting that most infected people do not experience symptoms. The article points to a recently published Nature Medicine study but the supplied excerpt does not provide its findings. A February 2026 Medscape report says eradication significantly reduced gastric cancer incidence and mortality in adults of nearly all ages, including those over 80, in a population-based study.
Risk and Prevention in Practice
A study of 371,813 veterans diagnosed with H. pylori found significantly higher gastric cancer risks among racial and ethnic minorities and smokers. It also reported that treatment reduced risk only when eradication was successful. Among Chinese adults, H. pylori infection is common and causes large numbers of gastric cancer cases; the cited study says population-based mass screening and eradication should be considered in high-risk settings. A separate correspondence raised concerns about that study’s finding on the association between H. pylori and cardia gastric cancer, so that specific association remains disputed in the supplied sources.
However, the study reinforces the importance of H. pylori screening and treatment, especially for individuals with a family history of gastric cancer or other risk factors. If you're concerned about your risk, talk to your doctor about appropriate screening and prevention strategies.
Ultimately, a combination of lifestyle modifications (such as a healthy diet and avoiding smoking), H. pylori eradication when necessary, and awareness of your genetic predispositions can empower you to take control of your gastric health.